arrow
E

Ehab Atallah

medical college of wisconsin
H指数:35
被引数:4,714

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

靶向CD38的双特异性抗体XmAb 18968在复发/难治性急性髓系白血病和T细胞急性淋巴细胞白血病患者中的应用

Leukemia
IF13.4
2026-09-140
PRE
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study
Leukemia
IF13.4
2026-08-310
PRE
Randomized trial of thulium laser-assisted tumor bed coagulation versus conventional suture renorrhaphy in laparoscopic partial nephrectomy: impact on perioperative outcomes and fibrosis biomarker response

钬激光辅助肿瘤床凝固术与常规缝合肾实质重建在腹腔镜部分肾切除术中的随机对照试验:对围手术期结局及纤维化生物标志物反应的影响

2025-12-170
OAAI
Outcomes of older patients with TP53-mutated myeloid neoplasms

TP53突变髓系肿瘤老年患者的结局

2025-10-070
OA
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status

TP53突变性骨髓增殖性肿瘤的结局异质性,基于疾病表型和突变状态

2025-05-220
PRE
US Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

美国专家共识:慢性期慢性粒细胞白血病(CML)对酪氨酸激酶抑制剂治疗的耐受不良定义

BLOOD
IF23.1
2024-11-050
PRE
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study
2024-09-100
PRE
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Blinatumomab治疗成人MRD阴性急性淋巴细胞白血病

2024-07-2511
PRE
Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
2024-05-303
OAAI
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis
2024-05-201
OAAI
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
2024-04-044
OAAI
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
2024-02-207
OAAI
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers
2024-02-114
OAAI